A Study to Assess the Accuracy of Magnetocardiography (MCG) to Diagnose True Ischemia in Patients With Chest Pain in the ED

Last updated: January 9, 2026
Sponsor: Mayo Clinic
Overall Status: Active - Enrolling

Phase

N/A

Condition

Chest Pain

Treatment

N/A

Clinical Study ID

NCT05809648
20-001225
  • Ages > 18
  • All Genders

Study Summary

The purpose of the research is to see if patients that come to the Emergency Department with chest pain can be more accurately and more quickly diagnosed by magnetocardiography (MCG) to see if their chest pain is caused by coronary ischemia (reduced blood flow to the heart) in patients with normal or have non-specific changes on the ECG vs other causes by other reasons.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients presenting to the ED with acute chest pain when an ACS is on thedifferential diagnosis.

  • Patient willing and able to give informed consent.

Exclusion

Exclusion Criteria:

  • ST elevation > 1 mm on any two contiguous ECG leads.

  • Hemodynamic instability (SBP >220 or <80, HR >160).

  • Pregnant patients.

  • Incarcerated patients (FMC patients).

  • Patients with a pacemaker or defibrillator.

  • Metal implants in the body (that are not MRI safe).

  • Patients that are unable to lie down in the MCG machine or stay still.

  • Patients who are unable to understand the informed consent process (ex: non-Englishspeakers without an available interpreter, cognitive delay).

  • Patients without the capacity to provide written informed consent

Study Design

Total Participants: 1000
Study Start date:
March 17, 2023
Estimated Completion Date:
December 31, 2026

Study Description

Hypothesis: MCG can accurately, and in real-time, identify an acute coronary syndrome for patients presenting to the emergency department (ED) with chest pain and is faster than current practice.

Aims, purpose, or objectives: Our primary objective is to measure the diagnostic accuracy of the Mesuron Avalon-H90 MCG device to detect ACS (unstable angina, NSTEMI) in Emergency Department patients who present with acute chest pain when compared to the current goal standard.

Our secondary objectives are as follows:

  • To study the ability of MCG to rule in or rule out ACS in real-time. We will assess the value of the MCG results in conjunction with the HEART pathway score. This will include looking at the diagnostic test accuracy, sensitivity and specificity of the device when used in conjunction with and without the HEART Pathway score, including versus excluding the troponin level (as the results of this is usually delayed by 45 minutes to 1 hour). In this way, we hope to demonstrate this technology may decrease ED length of stay in chest pain patients and decrease time to diagnosis. The comparison goal standard will be the Cardiology diagnosis, the result of serial troponins, or the ED diagnosis depending on the disposition of the patient.

  • To estimate ability of MCG for prognostication for major adverse cardiac events (MACE) at 3 days, 7 days, 30 days and 90 days.

Connect with a study center

  • Mayo Clinic Minnesota

    Rochester, Minnesota 55905
    United States

    Site Not Available

  • Mayo Clinic Minnesota

    Rochester 5043473, Minnesota 5037779 55905
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.